サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1540878

COVID-19診断薬市場レポート：製品タイプ、サンプルタイプ、検査タイプ、モード、最終用途、地域別 2024-2032

COVID-19 Diagnostics Market Report by Product Type, Sample Type, Test Type (Molecular Testing, Antigen-based Testing, Antibody Testing, and Others), Mode (Point-of-Care, Non-Point-of-Care ), End Use, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 142 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
COVID-19診断薬市場レポート：製品タイプ、サンプルタイプ、検査タイプ、モード、最終用途、地域別 2024-2032
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

COVID-19診断薬市場の世界市場規模は2023年に630億米ドルに達しました。IMARC Groupは、2032年までに同市場が306億米ドルに達すると予測しています。

COVID-19診断薬は、個人のウイルス感染の有無を検出するために実施される臨床検査を指します。COVID-19は、新たに発見された人獣共通感染症コロナウイルスによって引き起こされる感染症です。一般的な症状には、発熱、疲労、乾いた咳、息切れ、咽頭痛、体の痛みなどがあります。ウイルス感染は通常、逆転写酵素-ポリメラーゼ連鎖反応（RT-PCR）、抗原検査、抗体検査によって診断されます。これらの検査は、上咽頭（NP）、口腔咽頭（OP）、鼻腔ぬぐい液、唾液、血液からサンプルを採取するための試薬やキットを使用します。病院、研究所、診療所、研究機関、診断センターなどで広く使用されています。

コロナウイルス感染症の突然の発生や、世界中でCOVID-19の症例数が憂慮すべきほど増加していることは、市場成長の前向きな見通しを生み出している主な要因の一つです。日常的な症例数の継続的な増加は、患者に早期治療を提供するための迅速かつ包括的な検査のための診断検査の広範な採用につながっています。これに伴い、大量検査や分子診断の需要が増加していることが、市場の成長に寄与しています。さらに、新しい抗体検査キットや血清検査キットの発売など、さまざまな製品革新も成長を促す要因となっています。従来から使用されている検査キットと比較して、これらの変種は時間がかからず、正確な結果を得るためにソフトウェアベースのプログラムと統合することができます。その他、COVID-19感染のさらなる拡大を防ぐための政府の好意的な政策の実施や、特に新興経済諸国におけるヘルスケアインフラの大幅な改善などが、市場の成長を促進すると予測されています。

本レポートで扱う主な質問

  • 2023年の世界のCOVID-19診断薬市場の市場規模は？
  • 世界のCOVID-19診断薬市場に対するCOVID-19の影響は？
  • 世界のCOVID-19診断薬市場を牽引する主要因は何か？
  • 世界のCOVID-19診断薬市場の製品タイプ別内訳は？
  • 世界のCOVID-19診断薬市場のサンプルタイプ別内訳は？
  • 世界のCOVID-19診断薬市場の検査タイプ別の内訳は？
  • 世界のCOVID-19診断薬市場のモード別の内訳は？
  • COVID-19診断薬市場の世界における最終用途別の内訳は？
  • COVID-19診断薬市場の世界における主要地域は？
  • COVID-19診断薬市場の世界における主要企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のCOVID-19診断薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品タイプ別

  • 試薬とキット
    • 市場動向と予測
  • 機器
    • 市場動向と予測
  • その他
    • 市場動向と予測

第7章 市場内訳：サンプルタイプ別

  • 鼻咽頭スワブ
    • 市場動向と予測
  • 口腔咽頭スワブ
    • 市場動向と予測
  • 鼻腔スワブ
    • 市場動向と予測
  • 血
    • 市場動向と予測
  • その他
    • 市場動向と予測

第8章 市場内訳：検査タイプ別

  • 分子（RT-PCR）検査
    • 市場動向と予測
  • 抗原検査
    • 市場動向と予測
  • 抗体（血清学）検査
    • 市場動向と予測
  • その他
    • 市場動向と予測

第9章 市場内訳：モード別

  • ポイントオブケア（PoC）
    • 市場動向と予測
  • 非ポイントオブケア（非PoC）
    • 市場動向と予測

第10章 市場内訳：最終用途別

  • 研究所
    • 市場動向と予測
  • 病院
    • 市場動向と予測
  • 診断センターとクリニック
    • 市場動向と予測
  • その他
    • 市場動向と予測

第11章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向と予測
    • 市場内訳：国別

第12章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 価格分析

第16章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Becton Dickinson and Company
    • bioMerieux SA
    • Bio-Rad Laboratories
    • Danaher Corporation
    • F. Hoffman-La Roche Ltd.（Roche Holding AG）
    • Luminex Corporation
    • PerkinElmer Inc.
    • Quest Diagnostics Incorporated
    • Robert Bosch GmbH
    • Seegene Inc.
    • Siemens Aktiengesellschaft
    • Thermo Fisher Scientific Inc.
図表

List of Figures

  • Figure 1: Global: COVID-19 Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: COVID-19 Diagnostics Market: Sales Value (in Billion US$), 2024-2032
  • Figure 3: Global: COVID-19 Diagnostics Market: Breakup by Product Type (in %), 2023
  • Figure 4: Global: COVID-19 Diagnostics Market: Breakup by Sample Type (in %), 2023
  • Figure 5: Global: COVID-19 Diagnostics Market: Breakup by Test Type (in %), 2023
  • Figure 6: Global: COVID-19 Diagnostics Market: Breakup by Mode (in %), 2023
  • Figure 7: Global: COVID-19 Diagnostics Market: Breakup by End Use (in %), 2023
  • Figure 8: Global: COVID-19 Diagnostics Market: Breakup by Region (in %), 2023
  • Figure 9: Global: COVID-19 Diagnostics (Reagents and Kits) Market: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: COVID-19 Diagnostics (Instruments) Market: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: COVID-19 Diagnostics (Other Product Types) Market: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: COVID-19 Diagnostics (Nasopharyngeal Swabs) Market: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: COVID-19 Diagnostics (Oropharyngeal Swabs) Market: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: COVID-19 Diagnostics (Nasal Swabs) Market: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: COVID-19 Diagnostics (Blood) Market: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: COVID-19 Diagnostics (Other Sample Types) Market: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: COVID-19 Diagnostics (Molecular/RT-PCR Testing) Market: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: COVID-19 Diagnostics (Antigen-based Testing) Market: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: COVID-19 Diagnostics (Antibody-Testing- Serology) Market: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: COVID-19 Diagnostics (Other Test Types) Market: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: COVID-19 Diagnostics (Point-of-Care - PoC) Market: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: COVID-19 Diagnostics (Non-Point-of-Care - Non-PoC) Market: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: COVID-19 Diagnostics (Laboratories) Market: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: COVID-19 Diagnostics (Hospitals) Market: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: COVID-19 Diagnostics (Diagnostic Centers and Clinics) Market: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: COVID-19 Diagnostics (Other End Uses) Market: Sales Value (in Million US$), 2024-2032
  • Figure 27: North America: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 29: Canada: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 30: Asia-Pacific: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 31: China: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 32: Japan: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 33: India: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 34: South Korea: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 35: Australia: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 36: Indonesia: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 37: Others: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 38: Europe: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 39: Germany: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 40: France: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 41: United Kingdom: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 42: Italy: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 43: Spain: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 44: Russia: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 45: Others: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 46: Latin America: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 47: Brazil: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 48: Mexico: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 49: Others: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 50: Middle East and Africa: COVID-19 Diagnostics Market: Sales Value (in Million US$), 2024-2032
  • Figure 51: Middle East and Africa: COVID-19 Diagnostics Market: Breakup by Country (in %), 2023
  • Figure 52: Global: COVID-19 Diagnostics Industry: SWOT Analysis
  • Figure 53: Global: COVID-19 Diagnostics Industry: Value Chain Analysis
  • Figure 54: Global: COVID-19 Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: COVID-19 Diagnostics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: COVID-19 Diagnostics Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: COVID-19 Diagnostics Market Forecast: Breakup by Sample Type (in Million US$), 2024-2032
  • Table 4: Global: COVID-19 Diagnostics Market Forecast: Breakup by Test Type (in Million US$), 2024-2032
  • Table 5: Global: COVID-19 Diagnostics Market Forecast: Breakup by Mode (in Million US$), 2024-2032
  • Table 6: Global: COVID-19 Diagnostics Market Forecast: Breakup by End Use (in Million US$), 2024-2032
  • Table 7: Global: COVID-19 Diagnostics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: COVID-19 Diagnostics Market: Competitive Structure
  • Table 9: Global: COVID-19 Diagnostics Market: Key Players
目次
Product Code: SR112024A3552

The global COVID-19 diagnostics market size reached US$ 63.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 30.6 Billion by 2032.

COVID-19 diagnostics refer to the clinical tests conducted to detect the presence of the viral infection among individuals. COVID-19 is an infectious disease caused by the newly discovered zoonotic coronavirus. Some common symptoms include fever, fatigue, dry cough, shortness of breath, sore throat and body aches. The viral infection is usually diagnosed through reverse transcriptase-polymerase chain reaction (RT- PCR), antigen-based and antibody testing. These tests use reagents and kits to obtain the sample from nasopharyngeal (NP), oropharyngeal (OP) and nasal swabs, human saliva or blood. They are widely used in hospitals, laboratories, clinics, research institutes and diagnostic centers.

The sudden outbreak of coronavirus disease and an alarming increase in the number of COVID-19 cases across the globe are among the key factors creating a positive outlook for the market growth. The continuous rise in the number of daily cases has led to the widespread adoption of diagnostic tests for rapid and comprehensive testing to provide early treatment to the patients. In line with this, the increasing demand for mass testing and molecular diagnostics is contributing to the market growth. Additionally, various product innovations, such as the launch of novel antibody and serology test kits for home-testing, are acting as other growth-inducing factors. In comparison to the traditionally used testing kits, these variants are less time-consuming and can be integrated with software-based programs for accurate results. Other factors, including the implementation of favorable government polices to prevent the further spread of COVID-19 infection, along with significant improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global COVID-19 diagnostics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product type, sample type, test type, mode and end use.

Breakup by Product Type:

Reagents and Kits

Instruments

Others

Breakup by Sample Type:

Nasopharyngeal Swabs

Oropharyngeal Swabs

Nasal Swabs

Blood

Others

Breakup by Test Type:

Molecular (RT-PCR) Testing

Antigen-based Testing

Antibody (Serology) Testing

Others

Breakup by Mode:

Point-of-Care (PoC)

Non-Point-of-Care (Non-PoC)

Breakup by End Use:

Laboratories

Hospitals

Diagnostic Centers and Clinics

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories, Danaher Corporation, F. Hoffman-La Roche Ltd. (Roche Holding AG), Luminex Corporation, PerkinElmer Inc., Quest Diagnostics Incorporated, Robert Bosch GmbH, Seegene Inc., Siemens Aktiengesellschaft and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1. What was the size of the global COVID-19 diagnostics market in 2023?
  • 2. What has been the impact of COVID-19 on the global COVID-19 diagnostics market?
  • 3. What are the key factors driving the global COVID-19 diagnostics market?
  • 4. What is the breakup of the global COVID-19 diagnostics market based on the product type?
  • 5. What is the breakup of the global COVID-19 diagnostics market based on the sample type?
  • 6. What is the breakup of the global COVID-19 diagnostics market based on the test type?
  • 7. What is the breakup of the global COVID-19 diagnostics market based on the mode?
  • 8. What is the breakup of the global COVID-19 diagnostics market based on the end use?
  • 9. What are the key regions in the global COVID-19 diagnostics market?
  • 10. Who are the key players/companies in the global COVID-19 diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global COVID-19 Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Reagents and Kits
    • 6.1.1 Market Trends and Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends and Forecast
  • 6.3 Others
    • 6.3.1 Market Trends and Forecast

7 Market Breakup by Sample Type

  • 7.1 Nasopharyngeal Swabs
    • 7.1.1 Market Trends and Forecast
  • 7.2 Oropharyngeal Swabs
    • 7.2.1 Market Trends and Forecast
  • 7.3 Nasal Swabs
    • 7.3.1 Market Trends and Forecast
  • 7.4 Blood
    • 7.4.1 Market Trends and Forecast
  • 7.5 Others
    • 7.5.1 Market Trends and Forecast

8 Market Breakup by Test Type

  • 8.1 Molecular (RT-PCR) Testing
    • 8.1.1 Market Trends and Forecast
  • 8.2 Antigen-based Testing
    • 8.2.1 Market Trends and Forecast
  • 8.3 Antibody (Serology) Testing
    • 8.3.1 Market Trends and Forecast
  • 8.4 Others
    • 8.4.1 Market Trends and Forecast

9 Market Breakup by Mode

  • 9.1 Point-of-Care (PoC)
    • 9.1.1 Market Trends and Forecast
  • 9.2 Non-Point-of-Care (Non-PoC)
    • 9.2.1 Market Trends and Forecast

10 Market Breakup by End Use

  • 10.1 Laboratories
    • 10.1.1 Market Trends and Forecast
  • 10.2 Hospitals
    • 10.2.1 Market Trends and Forecast
  • 10.3 Diagnostic Centers and Clinics
    • 10.3.1 Market Trends and Forecast
  • 10.4 Others
    • 10.4.1 Market Trends and Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends and Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends and Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends and Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends and Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends and Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends and Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends and Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends and Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends and Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends and Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends and Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends and Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends and Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends and Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends and Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends and Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends and Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends and Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends and Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends and Forecast
    • 11.5.2 Market Breakup by Country

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Abbott Laboratories
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Becton Dickinson and Company
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 bioMerieux SA
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Bio-Rad Laboratories
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Danaher Corporation
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 F. Hoffman-La Roche Ltd. (Roche Holding AG)
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
    • 16.3.7 Luminex Corporation
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 PerkinElmer Inc.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Quest Diagnostics Incorporated
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Robert Bosch GmbH
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
    • 16.3.11 Seegene Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
    • 16.3.12 Siemens Aktiengesellschaft
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
      • 16.3.12.3 Financials
      • 16.3.12.4 SWOT Analysis
    • 16.3.13 Thermo Fisher Scientific Inc.
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio
      • 16.3.13.3 Financials
      • 16.3.13.4 SWOT Analysis